Owens O J, Stewart C, Leake R E, McNicol A M
Department of Biochemistry, Glasgow University, Scotland, U.K.
Anticancer Res. 1992 Sep-Oct;12(5):1455-8.
The presence of epidermal growth factor receptor (EGFR) was determined both by immunohistochemistry and ligand binding assay in 118 samples from 96 cases of ovarian cancer. EGFR was present in 47.5% of tumours biochemically and in 39.8% of tumours analysed immunohistochemically. The concordance rate for the techniques varied between 40% in endometrioid carcinomas to 85.7% in undifferentiated carcinomas with an overall concordance of 69.5% (p < 0.001). There was no significant difference between the presence of the high, low or high plus low affinity receptor components and tumour immunoreactivity. Although the ligand binding assay is more sensitive than immunohistochemistry for detecting the epidermal growth factor receptor, some cases are positive only on immunohistochemical screening. We would recommend that both techniques should be performed in prospective studies in order to elucidate the role of EGFR expression in ovarian cancer.
采用免疫组织化学和配体结合试验对96例卵巢癌患者的118份样本进行了表皮生长因子受体（EGFR）检测。生化检测显示47.5%的肿瘤存在EGFR，免疫组织化学分析显示39.8%的肿瘤存在EGFR。两种技术的一致性率在子宫内膜样癌中为40%，在未分化癌中为85.7%，总体一致性为69.5%（p<0.001）。高亲和力、低亲和力或高亲和力加低亲和力受体成分的存在与肿瘤免疫反应性之间无显著差异。虽然配体结合试验在检测表皮生长因子受体方面比免疫组织化学更敏感，但有些病例仅在免疫组织化学筛查时呈阳性。我们建议在前瞻性研究中同时采用这两种技术，以阐明EGFR表达在卵巢癌中的作用。
